Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alain E. Andrea"'
Autor:
Alain E. Andrea, Andrada Chiron, Guillaume Sarrabayrouse, Stéphanie Bessoles, Salima Hacein-Bey-Abina
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
In recent years, following the groundbreaking achievements of chimeric antigen receptor (CAR) T cell therapy in hematological cancers, and advancements in cell engineering technologies, the exploration of other immune cells has garnered significant a
Externí odkaz:
https://doaj.org/article/aa1b8a2a8ddf4e649776d6b5e057e544
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The presence of fucose on IgG1 Asn-297 N-linked glycan is the modification of the human IgG1 Fc structure with the most significant impact on FcɣRIII affinity. It also significantly enhances the efficacy of antibody dependent cellular cytotoxicity (
Externí odkaz:
https://doaj.org/article/462551c3f74843ca8a4aeb1dcad4b5e6
Autor:
Alain E. Andrea, Andrada Chiron, Sarah Mallah, Stéphanie Bessoles, Guillaume Sarrabayrouse, Salima Hacein-Bey-Abina
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
During this last decade, adoptive transfer of T lymphocytes genetically modified to express chimeric antigen receptors (CARs) emerged as a valuable therapeutic strategy in hematological cancers. However, this immunotherapy has demonstrated limited ef
Externí odkaz:
https://doaj.org/article/bc0b3529ba29475f88a47269a5c030e7
Autor:
Josée Golay, Alain E. Andrea
Publikováno v:
Antibodies, Vol 9, Iss 2, p 17 (2020)
Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms of action. Among thes
Externí odkaz:
https://doaj.org/article/1ffb66dbe0fa451191d08fde60bb6b4b
Autor:
Alain E. Andrea, Andrada Chiron, Sarah Mallah, Stéphanie Bessoles, Guillaume Sarrabayrouse, Salima Hacein-Bey-Abina
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
During this last decade, adoptive transfer of T lymphocytes genetically modified to express chimeric antigen receptors (CARs) emerged as a valuable therapeutic strategy in hematological cancers. However, this immunotherapy has demonstrated limited ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2af678d53cd3a383355fe37d31078d76
https://pubmed.ncbi.nlm.nih.gov/35211124
https://pubmed.ncbi.nlm.nih.gov/35211124
Publikováno v:
International Journal of Molecular Sciences
Immunoadoptive therapy with genetically modified T lymphocytes expressing chimeric antigen receptors (CARs) has revolutionized the treatment of patients with hematologic cancers. Although clinical outcomes in B-cell malignancies are impressive, resea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a0d9bb7c540a7e90b20d051e923a11a
https://pubmed.ncbi.nlm.nih.gov/33207607
https://pubmed.ncbi.nlm.nih.gov/33207607
Autor:
Alain E. Andrea, Josée Golay
Publikováno v:
Antibodies, Vol 9, Iss 17, p 17 (2020)
Antibodies
Antibodies
Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms of action. Among thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15019061e7a84ff61a85e34e52d7780
https://www.mdpi.com/2073-4468/9/2/17
https://www.mdpi.com/2073-4468/9/2/17